Bristol Myers Squibb (BMY) Share-based Compensation (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Share-based Compensation for 18 consecutive years, with $135.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Share-based Compensation fell 1.46% year-over-year to $135.0 million in Q2 2026; TTM through Jun 2026 was $553.0 million, a 4.34% increase from a year earlier, with the FY2025 full-year figure at $553.0 million, up 9.07% from the prior year.
• Share-based Compensation was $135.0 million for Q2 2026 at Bristol Myers Squibb, down from $146.0 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $146.0 million in Q1 2026 and troughed at $107.0 million in Q1 2022.
• A 5-year average of $128.7 million and a median of $130.5 million in 2023 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation declined 29.14% in 2022 and gained 18.1% in 2023, its largest moves.
• Over 5 years, Share-based Compensation stood at $119.0 million in 2022, then gained by 6.72% to $127.0 million in 2023, then dropped by 5.51% to $120.0 million in 2024, then grew by 10.83% to $133.0 million in 2025, then rose by 1.5% to $135.0 million in 2026.
• The last three Share-based Compensation figures came in at $135.0 million (Q2 2026), $146.0 million (Q1 2026), and $133.0 million (Q4 2025), per Business Quant data.